HKU Scholars Hub: Browsing DSpace

Browsing by Author Schluep, T

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 20 of 22 next >

Title	Author(s)	Issue Date
A phase 1 study to evaluate safety and tolerability of escalating single doses of the hepatitis B virus RNA interference drug ARC-521 in a healthy volunteer population Proceeding/Conference:Journal of Hepatology	Gane, E Schwabe, C Given, B Schluep, T Hamilton, J Lai, CL Locarnini, S Lau, J Ferrari, C Gish, R	2017
Chronic hepatitis B: Virology, natural history, current management and a glimpse at future opportunities Journal:Antiviral Research	Gish, RG Given, BD Lai, CL Locarnini, SA Lau, JYN Lewis, DL Schluep, T	2015
Combination treatments including the small-interfering RNA JNJ-3989 induce rapid and sometimes prolonged viral responses in patients with CHB Journal:Journal of Hepatology	Yuen, MF Locarnini S Lim, TH Strasser, SI Sievert W Cheng, W Thompson, AJ Given, BD Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont, M Lenz, O De Ridder, F Cloherty, G Wong, DKH Schwabe, C Jackson, K Lai, CL Gish, RG Gane, E	14-Oct-2022
Differential reductions in viral antigens expressed from cccDNAVS integrated DNA in treatment naïve HBeAg positive and negative patients with chronic HBV after RNA interference therapy with ARC-520 Proceeding/Conference:Journal of Hepatology	Yuen, RMF Chan, HLY Liu, K Given, BD Schluep, T Hamilton, J Lai, CL Locarnini, SA Lau, JYN Ferrari, C Gish, RG	2016
Dose response with the RNA interference (RNAi) therapy JNJ-3989 combined with nucleos(t)ide analogue (NA) treatment in expanded cohorts of patients (pts) with chronic hepatitis B (CHB) Proceeding/Conference:Hepatology	Gane, EJ Locarnini, S Lim, TH Strasser, SI Sievert, W Cheng, W Thompson, A Given, BD Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2019
Effective inhibition of cccDNA derived mRNA/viral antigens and tolerability with ARC-520 Proceeding/Conference:Hepatology International	Yuen, RMF Chan, HLY Liu, SHK Given, BD Schluep, T Hamilton, J Lai, CL Locarnini, SA Lau, JYN Ferrari, C Gish, RG	2016
First clinical experience with RNA interference [RNAI]-based triple combination therapy in chronic hepatitis B (CHB): JNJ-73763989 (JNJ-3989), JNJ-56136379 (JNJ-6379) and a nucleos(t)ide analogue (NA) Proceeding/Conference:Hepatology	Yuen, RMF Locarnini, S Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O Cloherty, G Jackson, K Ferrari, C Lai, CL Liu, SHK Mak, LY Wong, DKH To, WP Ko, KL Gish, RG	2019
First results with RNA interference (RNAi) in chronic hepatitis b (CHB) using ARO-HBV Proceeding/Conference:Hepatology	Gane, EJ Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Li, Z Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2018
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in patients with chronic hepatitis B Journal:Antiviral Therapy	Gane, E Yuen, MF Kakuda, TN Ogawa, T Takahashi, Y Goeyvaerts, N Lonjon-Domanec, I Vaughan, T Schluep, T Hamilton, J Ediage, EN Hillewaert, V Snoeys, J Lenz, O Talloen, W Biermer, M	1-Apr-2022
Long-term serological, virological and histological responses to RNA inhibition by ARC-520 in Chinese chronic hepatitis B patients on entecavir treatment Journal:Gut	Yuen, MF Wong, DKH Schluep, T Lai, CL Ferrari, C Locarnini, S Lo, RCL Gish, R Hamilton, J Wooddell, CI Mak, LY Given, BD	2021
Predicting HBsAg clearance responses during ARC-520 RNA interference (RNAi) therapy based on HBsAg epitope profile analysis Proceeding/Conference:Journal of Hepatology	Walsh, R Yuen, L Hammond, R Deerain, J Given, B Schluep, T Yuen, MF Chan, HLY Lai, CL Hamilton, J Lau, JY Ferrari, C Gish, RG Locarnini, SA	2016
Prolonged RNA interference therapy with ARC-520 Injection in treatment naïve, HBeAg positive and negative patients with chronic HBV results in significant reductions of HBs antigen Proceeding/Conference:Journal of Hepatology	Yuen, RMF Liu, SHK Chan, HLY Given, BD Schluep, T Hamilton, J Lai, CL Locarnini, SA Lau, JY Ferrari, C Gish, RG	2017
RNA interference therapy with ARC-520 Injection results in long term off-therapy antigen reductions in treatment naïve, HBeAg positive and negative patients with chronic HBV Proceeding/Conference:Journal of Hepatology	Yuen, RMF Liu, SHK Given, B Schluep, T Hamilton, J Lai, CL Locarnini, S Jackson, K Lai, JY Ferrari, C Gish, RG.	2018
RNA Interference Therapy With ARC‐520 Results in Prolonged Hepatitis B Surface Antigen Response in Patients With Chronic Hepatitis B Infection Journal:Hepatology	Yuen, MF Schiefke, I Yoon, JH Ahn, SH Heo, J Kim, JH Chan, HLY Yoon, KT Klinker, H Manns, M Petersen, J Schluep, T Hamilton, J Given, BD Ferrari, C Lai, CL Locarnini, SA Gish, RG	2020
RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg Journal:Science Translational Medicine	Wooddell, CI Yuen, RMF Chan, HLY Gish, RG Locarnini, SA Chavez, D Ferrari, C Given, BD Hamilton, J Kanner, SB Lai, CL Lai, JYN Schluep, T Xu, Z Lanford, RE Lewis, DL	2017
Safety, Tolerability, and Pharmacokinetics of ARC-520 Injection, an RNA Interference-Based Therapeutic for the Treatment of Chronic Hepatitis B Virus Infection, in Healthy Volunteers Journal:Clinical Pharmacology in Drug Development	Schluep, T Lickliter, J Hamilton, J Lewis, DL Lai, CL Lau, JYN Locarnini, SA Gish, RG Given, BD	2017
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Proceeding/Conference:Journal of Hepatology	Gane, E Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O De Ridder, F Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2021
Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B (CHB) shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors Proceeding/Conference:APASL 2022, Seoul, Korea, 30 Mar - 3 Apr 2022. Hepatology International	Gane, E Locarnini, S Lim, TH Strasser, SI Sievert, W Cheng, W Thompson, AJ Given, BD Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont, M Lenz, O Ridder, FD Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, R Yuen, RMF	2022
Short term RNA interference therapy in chronic hepatitis B using JNJ-3989 brings majority of patients to HBsAg < 100 IU/ml threshold Proceeding/Conference:Journal of Hepatology	Yuen, RMF Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Gane, E	2019
Short-term treatment with RNA interference therapy, JNJ-3989, results in sustained hepatitis B surface antigen suppression in patients with chronic hepatitis B receiving nucleos(t)ide analogue treatment Proceeding/Conference:Journal of Hepatology	Gane, E Locarnini, S Lim, TH Strasser, S Sievert, W Cheng, W Thompson, A Given, B Schluep, T Hamilton, J Biermer, M Kalmeijer, R Beumont-Mauviel, M Lenz, O Cloherty, G Wong, DKH Schwabe, C Jackson, K Ferrari, C Lai, CL Gish, RG Yuen, RMF	2020

Showing results 1 to 20 of 22 next >